Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Cash from Operations: 2023-2025

Historic Cash from Operations for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to -$32.8 million.

  • NewAmsterdam Pharma Co N.V's Cash from Operations fell 162.11% to -$32.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$144.4 million, marking a year-over-year increase of 6.34%. This contributed to the annual value of -$158.6 million for FY2024, which is 12.28% down from last year.
  • As of Q3 2025, NewAmsterdam Pharma Co N.V's Cash from Operations stood at -$32.8 million, which was up 13.01% from -$37.7 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Cash from Operations registered a high of -$12.5 million during Q3 2024, and its lowest value of -$54.6 million during Q1 2024.
  • Its 3-year average for Cash from Operations is -$37.0 million, with a median of -$36.5 million in 2025.
  • Its Cash from Operations has fluctuated over the past 5 years, first surged by 73.39% in 2024, then crashed by 162.11% in 2025.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's Cash from Operations (Quarterly) stood at -$33.1 million in 2023, then fell by 13.32% to -$37.5 million in 2024, then slumped by 162.11% to -$32.8 million in 2025.
  • Its Cash from Operations was -$32.8 million in Q3 2025, compared to -$37.7 million in Q2 2025 and -$36.5 million in Q1 2025.